Leukopheresis for profound hyperleukocytosis

Therapeutic leukocyte reduction for acute and chronic myeloid leukemias: A 4-year experience from an oncology center in India

“…[ 5 6 7 8 9 10 11 16 17 18 19 ] Our patients had a low frequency of neurological (3/10) or hemorrhagic (0/10) symptoms secondary to leukostasis compared to that reported in literature. [ 6 7 9 10 17 18 19 ] Priapism was the only symptom in the cases of CML. We performed TLR promptly on the request of the treating physician.…”

“…The biochemical values and procedural parameters of our case series are comparable to those published by other centers. [ 5 6 7 16 17 ]…”

Hyperleukocytosis and leukocytapheresis in acute leukaemias: experience from a single centre and review of the literature of leukocytapheresis in acute myeloid leukaemia

“…In our opinion, the major disease compartment in these disorders is probably the extravascular bone marrow and eventually lymphoid organs, however the procedure is also effective with regard to reduction of leukocyte levels and decreased levels are maintained without rapid replacement of circulating cells from the bone marrow. Finally, a recent report suggested that leukocytapheresis did not only reduce leukocyte levels, the procedure also seems to normalise the circulation because these patients may have an increased blood volume that is restored and the reduction of the circulating leukaemia cell burden may therefore be larger than reflected in the reduction of the leukocyte count (Chekol et al , ).…”

Exchange transfusion in patients with Down syndrome and severe transient leukemia

“…Respiratory failure may be associated with hyperviscosity derived from hyperleukocytosis in patients with leukemia and TL . An increase in WBC count >100 × 10 9 /L may correspond to an increase in hematocrit (or leukocrit) by 4.0 points . Although the safety and beneficial effects of exchange transfusion (ExT) on cytoreduction in leukemia patients with hyperleukocytosis have been demonstrated, and ExT has been used empirically in TL patients, its effects in TL patients with hyperleukocytosis are poorly understood.…”